{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:15:32Z","timestamp":1785374132919,"version":"3.55.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic hepatitis B, a major cause of liver disease and cancer, affects &amp;gt;250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.<\/jats:p>","DOI":"10.1093\/cid\/ciad506","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T22:18:36Z","timestamp":1693088316000},"page":"983-990","source":"Crossref","is-referenced-by-count":9,"title":["Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1484-4752","authenticated-orcid":false,"given":"Marion G","family":"Peters","sequence":"first","affiliation":[{"name":"Department of Medicine, Northwestern University , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine & State Key Laboratory of Liver Research, The University of Hong Kong , Hong Kong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Terrault","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fry","sequence":"additional","affiliation":[{"name":"Aligos Therapeutics, Clinical Development Consultant , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan , Italy"},{"name":"Department of Pathophysiology and Transplantation, CRC \u201cA. M. and A. Migliavacca\u201d Center for Liver Disease, University of Milan , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Gane","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland , Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Hwang","sequence":"additional","affiliation":[{"name":"Vir Biotechnology , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M","family":"Stamm","sequence":"additional","affiliation":[{"name":"Assembly Biosciences , South San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Leus","sequence":"additional","affiliation":[{"name":"Forum for Collaborative Research, University of California, Berkeley School of Public Health , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala K","family":"Maini","sequence":"additional","affiliation":[{"name":"Institute of Immunity and Transplantation, University College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mendez","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Warren, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lonjon-Domanec","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica , Issy les Moulineaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Leipzig University Medical Center , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wang","sequence":"additional","affiliation":[{"name":"Cooperman Barnabas Medical Center, RWJBarnabas-Rutgers Medical Group , Livingston, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Mishra","sequence":"additional","affiliation":[{"name":"Division of Antivirals, Center for Drug Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Donaldson","sequence":"additional","affiliation":[{"name":"Division of Antivirals, Center for Drug Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Buchholz","sequence":"additional","affiliation":[{"name":"Department 32 Infectiology, Dermatology and Allergology, Federal Institute for Drugs and Medical Devices , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[{"name":"Forum for Collaborative Research, University of California, Berkeley School of Public Health , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"key":"2024041017074076700_ciad506-B1","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV\/HDV Treatment Endpoints Conference","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"2024041017074076700_ciad506-B2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2024041017074076700_ciad506-B3","author":"US FDA Center for Drug Evaluation and Research","year":"2022"},{"key":"2024041017074076700_ciad506-B4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"2024041017074076700_ciad506-B5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"2024041017074076700_ciad506-B6","doi-asserted-by":"crossref","first-page":"S1147","DOI":"10.1016\/S0168-8278(23)03281-6","article-title":"Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial","volume":"78","author":"van Bommel","year":"2023","journal-title":"J Hepatol"},{"key":"2024041017074076700_ciad506-B7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/hep.32231","article-title":"Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort","volume":"75","author":"Terrault","year":"2022","journal-title":"Hepatology"},{"key":"2024041017074076700_ciad506-B8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"2024041017074076700_ciad506-B9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"2024041017074076700_ciad506-B10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.14309\/ajg.0000000000002125","article-title":"Randomized trial of tenofovir with or without peginterferon alfa followed by protocolized treatment withdrawal in adults with chronic hepatitis B","volume":"118","author":"Terrault","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2024041017074076700_ciad506-B11","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.2147\/IJGM.S321253","article-title":"Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B","volume":"14","author":"Liao","year":"2021","journal-title":"Int J Gen Med"},{"key":"2024041017074076700_ciad506-B12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12072-021-10159-w","article-title":"Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation","volume":"15","author":"Kuo","year":"2021","journal-title":"Hepatol Int"},{"issue":"suppl 1","key":"2024041017074076700_ciad506-B13","first-page":"1","article-title":"Severe hepatitis flare and related mortality after discontinuation of oral antiviral treatment in patients with chronic hepatitis B: a population based study","volume":"74","author":"Hsu","year":"2021","journal-title":"Hepatology"},{"key":"2024041017074076700_ciad506-B14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2024041017074076700_ciad506-B15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijid.2019.07.036","article-title":"Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: a meta-analysis","volume":"86","author":"Liu","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2024041017074076700_ciad506-B16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12876-020-01263-6","article-title":"HBsag quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2024041017074076700_ciad506-B17","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024041017074076700_ciad506-B18","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/hepr.13504","article-title":"Japan Society of Hepatology guidelines for the management of hepatitis B virus infection: 2019 update","volume":"50","author":"The Japan Society of Hepatology Drafting Committee for Hepatitis Management Guidelines","year":"2020","journal-title":"Hepatol Res"},{"key":"2024041017074076700_ciad506-B19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B","volume":"222","author":"Fan","year":"2020","journal-title":"J Infect Dis"},{"key":"2024041017074076700_ciad506-B20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg &lt;100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J Gastroenterol"},{"key":"2024041017074076700_ciad506-B21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jhep.2022.02.020","article-title":"Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection","volume":"77","author":"Gehring","year":"2022","journal-title":"J Hepatol"},{"key":"2024041017074076700_ciad506-B22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"2024041017074076700_ciad506-B23","first-page":"522A","article-title":"Treatment with bepirovirsen (GSK3228836) leads to hepatitis B surface antigen (HBsAg) reduction and cytokine\/chemokine responses linked to innate and adaptive immunity in a phase 2a, randomized, double-blind, placebo-controlled study","volume":"74","author":"Singh","year":"2021","journal-title":"Hepatology"},{"key":"2024041017074076700_ciad506-B24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"2024041017074076700_ciad506-B25","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)Ide analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"2024041017074076700_ciad506-B26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep4.1626","article-title":"Pilot study using machine learning to identify immune profiles for the prediction of early virological relapse after stopping nucleos(t)ide analogues in HBeAg-negative CHB","volume":"5","author":"W\u00fcbbolding","year":"2021","journal-title":"Hepatol Commun"},{"key":"2024041017074076700_ciad506-B27","first-page":"767","article-title":"Liver sampling: a vital window into HBV pathogenesis on the path to functional cure","volume":"67","author":"Gill","year":"2018","journal-title":"Gut"},{"key":"2024041017074076700_ciad506-B28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(21)00475-1","article-title":"A call for advocacy and patient voice to eliminate hepatitis B virus infection","volume":"7","author":"Matthews","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024041017074076700_ciad506-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/JTS.1000467","article-title":"Attitudes towards clinical trial participation among people living with chronic hepatitis B","volume":"8","author":"Ibrahim","year":"2022","journal-title":"J Transl Sci"},{"key":"2024041017074076700_ciad506-B30","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003239","article-title":"Hepatitis B infection or reactivation after switch to two-drug antiretroviral therapy: a case series, literature review, and management discussion","author":"Vasishta","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024041017074076700_ciad506-B31","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"2024041017074076700_ciad506-B32","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"2024041017074076700_ciad506-B33","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(22)00538-4","article-title":"ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (envafolimab) plus nucleos(t)ide analogs","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"2024041017074076700_ciad506-B34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"2024041017074076700_ciad506-B35","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.14309\/ajg.0000000000002176","article-title":"Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: outcomes from the withdrawal phase of the HBRN immune active treatment trial","volume":"118","author":"Feld","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"suppl 1","key":"2024041017074076700_ciad506-B36","first-page":"S1","article-title":"Efficacy and safety of combination treatment with siRNA JNJ-73763989 and capsid assembly modulator JNJ-56136379 (bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B patients: follow-up week 48 end of study results from REEF-2","volume":"76","author":"Agarwal","year":"2022","journal-title":"Hepatol"},{"key":"2024041017074076700_ciad506-B37","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"2024041017074076700_ciad506-B38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B","volume":"23","author":"Papatheodoridis","year":"2017","journal-title":"Antiviral Therapy"},{"key":"2024041017074076700_ciad506-B39","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"2024041017074076700_ciad506-B40","doi-asserted-by":"crossref","first-page":"e161818","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment","volume":"132","author":"Grudda","year":"2022","journal-title":"J Clin Invest"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad506\/51532927\/ciad506.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/4\/983\/57208591\/ciad506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/4\/983\/57208591\/ciad506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T18:10:33Z","timestamp":1712772633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/4\/983\/7252325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,26]]},"published-print":{"date-parts":[[2024,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad506","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,15]]},"published":{"date-parts":[[2023,8,26]]}}}